Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational study

Bingham, Clifton O.; Ince, Akgun; Keystone, Edward; Chon, Yun

doi:10.1185/03007990902841010

Cited by 35 publications

(28 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the studies by Buch et al 99 and Bingham et al 104 lack of efficacy was the primary reason for switching to ETN. In studies by Haraoui et al, 98 Cohen et al 100 and Buch et al 101 patients discontinued IFX owing to a lack of efficacy or safety.…”

Section: Etanerceptmentioning

confidence: 99%

“…100,102 Full details of the quality assessment are reported in Table 11. With the 100 Only one study 104 reported the percentage of patients lost to follow-up (0.5%). Table 12 and Table 13 show what outcomes were measured in each study.…”

Section: Quality Assessmentmentioning

confidence: 99%

“…Five were prospective 98,99,101,103,104 and two were retrospective. 100,102 Full details of the quality assessment are reported in Table 11.…”

Section: Quality Assessmentmentioning

confidence: 99%

“…101 The other studies were carried out in France, 100 Italy, 102 Finland 103 and the USA. 98 One study 104 was a multicentre study that enrolled patients from both the USA and Canada. The length of follow-up varied from 12 weeks to more than 9 months.…”

Section: Figurementioning

confidence: 99%

“…Seven uncontrolled observational studies [98][99][100][101][102][103][104] were identified that assessed efficacy of ETN.…”

Section: Etanerceptmentioning

confidence: 99%

See 4 more Smart Citations

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation

Malottki

Barton²,

Tsourapas³

et al. 2011

Health Technol Assess

229

150

View full text Add to dashboard Cite

An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTAAdalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation Dr Paresh Jobanputra has participated in several technology assessments/appraisals related to rheumatoid arthritis as the clinical expert of the assessment group. He works as consultant rheumatologist in a large department of rheumatology. His department has taken part in clinical trials of etanercept, adalimumab, rituximab and tocilizumab. The department receives funding for nurses from Schering-Plough Ltd to administer infliximab to patients currently being treated with this drug. Currently he is the chief investigator of a clinical trial comparing adalimumab versus etanercept (ISRCTN95861172). He has, in the past, received support for educational purposes from Wyeth Pharmaceuticals (etanercept), Abbott (adalimumab) and Roche (rituximab). He has also been involved in an advisory board for Roche in relation to tocilizumab and rituximab, and has accept...

show abstract

Section: Etanerceptmentioning

confidence: 99%

Section: Quality Assessmentmentioning

confidence: 99%

“…Five were prospective 98,99,101,103,104 and two were retrospective. 100,102 Full details of the quality assessment are reported in Table 11.…”

Section: Quality Assessmentmentioning

confidence: 99%

Section: Figurementioning

confidence: 99%

“…Seven uncontrolled observational studies [98][99][100][101][102][103][104] were identified that assessed efficacy of ETN.…”

Section: Etanerceptmentioning

confidence: 99%

See 3 more Smart Citations

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation

Malottki

Barton²,

Tsourapas³

et al. 2011

Health Technol Assess

229

150

View full text Add to dashboard Cite

show abstract

MAbs Targeting Soluble Mediators in Phase 1 and 2 Clinical Studies Immunological Disorders

Brennan

2014

Handbook of Therapeutic Antibodies

View full text Add to dashboard Cite

Two Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis

Fürst

Shaikh

Greenwald

et al. 2015

Arthritis Care & Research

View full text Add to dashboard Cite

ObjectiveTo investigate clinical efficacy and safety of 2 certolizumab pegol (CZP) maintenance dosing regimens plus methotrexate (MTX) in active rheumatoid arthritis (RA) patients achieving the American College of Rheumatology 20% improvement criteria (ACR20) after the CZP 200 mg every 2 weeks open-label run-in period.MethodsDOSEFLEX (dosing flexibility) was a double-blind, placebo-controlled randomized study with an open-label run-in phase. During the run-in phase, all patients received CZP 400 mg (weeks 0, 2, and 4) and 200 mg every 2 weeks to week 16. Week 16 ACR20 responders were randomized 1:1:1 at week 18 to CZP 200 mg every 2 weeks, 400 mg every 4 weeks, or placebo.ResultsA total of 209 (of 333) patients were randomized at week 18 (CZP: 200 mg, n = 70; 400 mg, n = 70; placebo, n = 69). Groups had similar baseline characteristics (week 0). Week 34 ACR20 response rates were comparable between the CZP 200 mg every 2 weeks and the 400 mg every 4 weeks groups (67.1% versus 65.2%), which was significantly higher than placebo (44.9%; P = 0.009 and P = 0.017). ACR50/70 and remission criteria were met more frequently in CZP groups than placebo at week 34, with similar responses between anti–tumor necrosis factor–experienced and naive patients. Improvements from baseline Disease Activity Score in 28 joints using the erythrocyte sedimentation rate and Health Assessment Questionnaire disability index scores were maintained in CZP groups from week 16 to 34 while worsening on placebo. Adverse event (AE) rates in the double-blind phase were 62.9% versus 60.9% versus 62.3%; serious AE rates were 7.1% versus 2.9% versus 0.0% (CZP 200 mg, 400 mg, and placebo groups).ConclusionIn active RA patients with an incomplete MTX response, CZP 200 mg every 2 weeks and 400 mg every 4 weeks were comparable and better than placebo for maintaining clinical response to week 4 following a 16-week, open-label run-in phase.

show abstract

Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational study

Cited by 35 publications

References 29 publications

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation

MAbs Targeting Soluble Mediators in Phase 1 and 2 Clinical Studies Immunological Disorders

Two Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis

Contact Info

Product

Resources

About